ACAD
32.21
+0.33
+1.05%
AEMD
0.27
+0.01
+4.83%
APRI
1.22
0.00
0.00%
ARNA
4.65
+0.1
+2.09%
ATEC
1.35
-0.02
-1.46%
CFN
59.8
+0.03
+0.05%
CNAT
5.74
+0.4
+7.49%
CRXM
0.2
0.00
-1.00%
CYTX
0.49
+0.01
+1.69%
DXCM
62.7
+4.76
+8.22%
GNMK
13.22
+0.07
+0.49%
HALO
14.42
+0.55
+3.97%
ILMN
201.52
+4.36
+2.21%
INNV
0.23
-0.02
-9.96%
INO
8.85
+0.24
+2.79%
ISCO
0.06
0.00
-1.67%
ISIS
72.86
+1.58
+2.22%
LGND
55.96
+1.29
+2.36%
LPTN
2.97
+0.01
+0.34%
MBVX
1.17
+0.03
+2.63%
MEIP
3.72
+0.03
+0.81%
MNOV
3.58
+0.03
+0.85%
MRTX
20
+0.73
+3.79%
MSTX
0.46
-0.01
-3.17%
NBIX
33.49
+1.79
+5.65%
NUVA
46.83
+0.07
+0.15%
ONCS
0.4
0.00
-0.50%
ONVO
6.74
+0.42
+6.65%
OREX
5.57
+0.16
+2.96%
OTIC
31.82
-1.12
-3.39%
QDEL
24.68
+0.36
+1.48%
RCPT
115.93
+5.83
+5.30%
RGLS
19.42
+0.88
+4.75%
RMD
67.16
+1.92
+2.94%
SCIE
0.01
0.00
0.00%
SPHS
0.46
0.00
-1.07%
SRNE
10.61
+0.64
+6.42%
TROV
5.93
+0.13
+2.24%
VICL
1.05
+0.01
+0.48%
VOLC
17.97
+0.01
+0.03%
ZGNX
1.32
+0.04
+3.13%
Home » Archive by Category

Xconomy

More Biotechs Belly-Up These Days but Dendreon Still “One of a Kind”

December 2, 2014 – 4:31 am | Edit Post

Biotech companies rarely go bankrupt. Sitting where I sit, that bit of conventional wisdom comes around every so often, although it doesn’t generate quite the same buzz as Halley’s Comet…
[[Click headline to continue reading.]]

Prescription Drug Pricing: The Fine Line Between Value and Greed

December 2, 2014 – 1:00 am | Edit Post

Value. It’s one of the most frequently used buzzwords on both Wall Street and in healthcare. Virtually every press release from a publicly traded company assures us that its latest…
[[Click headline to continue reading.]]

Prescription Drug Pricing: The Fine Line Between Value and Greed

December 2, 2014 – 1:00 am | Edit Post

Value. It’s one of the most frequently used buzzwords on both Wall Street and in healthcare. Virtually every press release from a publicly traded company assures us that its latest…
[[Click headline to continue reading.]]

BioNano Raises $53M to Identify “Structural Variations” in Genome

November 20, 2014 – 5:44 pm | Edit Post

[Corrected 11/24/14, 12 pm. See below.] San Diego-based BioNano Genomics, which has taken a fundamentally different approach to analyzing the genome, says today it has closed on $53 million in Series…

[[Click headline to continue reading.]]

BioNano Raises $53M to Identify “Structural Variations” in Genome

November 20, 2014 – 5:44 pm | Edit Post

[Corrected 11/24/14, 12 pm. See below.] San Diego-based BioNano Genomics, which has taken a fundamentally different approach to analyzing the genome, says today it has closed on $53 million in Series…

[[Click headline to continue reading.]]

West Coast Biotech Roundup: Gilead, Juno, Hutch, Fibrogen & More

November 20, 2014 – 2:21 pm | Edit Post

Snow? What snow? The only thing piling up at astonishing rates on the West Coast this week is biotech news. Up in Seattle, the Fred Hutchinson Cancer Research Center has unveiled its new president,…

[[Click headline to continue reading.]]

West Coast Biotech Roundup: Gilead, Juno, Hutch, Fibrogen & More

November 20, 2014 – 2:21 pm | Edit Post

Snow? What snow? The only thing piling up at astonishing rates on the West Coast this week is biotech news. Up in Seattle, the Fred Hutchinson Cancer Research Center has unveiled its new president,…

[[Click headline to continue reading.]]

Breaking Bottlenecks, Opening the Floodgates to Genomic Data

November 18, 2014 – 4:00 am | Edit Post

There is a major transformational step underway for managing the growing amount of human genomic data. To date, the focus has been on amassing databanks of genomes and then developing new tools to…

[[Click headline to continue reading.]]

New Study Shows How ZMapp Binds to Ebola, Ways to Boost Potency

November 17, 2014 – 2:18 pm | Edit Post

Scientists at The Scripps Research Institute have produced the first 3-D image of how the ZMapp drug developed by San Diego’s Mapp Biopharmaceutical binds to the Ebola virus, providing new insights…
[[Click headline to continue reading.]]

New Research Could (Finally) Remove RNAi’s Commercial Limitations

November 17, 2014 – 9:05 am | Edit Post

[Corrected 11/17/14, 12:30pm. See below.] If nothing else, the acronym RNAi, which stands for ribonucleic acid interference, should be familiar to biotech observers as something that won two…

[[Click headline to continue reading.]]